Endometrial Cancer Patientes MMR Deficient Comparing Chimiotherapy vs Dostarlimab in First Line
Status:
Not yet recruiting
Trial end date:
2029-05-01
Target enrollment:
Participant gender:
Summary
Phase 3, randomized, multicentre study to evaluate the efficacy and safety of dostarlimab
versus carboplatin-paclitaxel in patients with MMR deficient relapse or advanced endometrial
cancer.